This page is for healthcare professionals. If you are not a healthcare professional, please click here.
Emylif is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults.
1
Simplicity, precision and reassurance.
Behind every dose.
Now available in the UK for ALS patients
*Demonstration packs do not contain riluzole and are for marketing purposes only.
1. Emylif (riluzole). Summary of product characteristics.
A simple way for ALS patients to take riluzole
Emylif offers ALS patients and their carers the simplicity of convenient administration regardless of symptomatic burden (Emylif SmPC), reducing the likelihood of administration errors (Bennett et al, 2013; Kelly et al, 2011; Dyer et al, 2017; Royal Pharma Soc, 2022), and reassuring you that they will receive the full prescribed dose every time (Aquestive, 2022; Di Stefano et al, 2022).
Emylif is easy to administer regardless of patients’ capacity to swallow, and requires less assistance, helping patients retain independence (Emylif SmPC; Aquestive, 2022).
For simplicity...without the burden of challenging administration and preparation steps for patients or their carers (Teglutik SmPC; Data on file EN011, 2022; Onesti et al, 2017)
.png)
For precision of dosing...without increasing the likelihood of administration errors (Bennett et al, 2013; Kelly et al, 2011; Dyer et al, 2017; Royal Pharma Soc, 2022)
Emylif oral film technology delivers the full prescribed dose every time (Aquestive, 2022; Di Stefano et al, 2022).
.png)
For reassurance...without need to change or modify treatment formulation throughout disease progression (Dyer et al, 2017)
Emylif reduces the risk of aspiration, contamination and underdosing (Di Stefano et al, 2022; ClinicalTrials.gov, 2022; Data on file CSR; Dyer et al, 2017) and offers treatment continuity of riluzole across ALS disease progression.
References
Emylif (riluzole). Summary of Product Characteristics
Bennett B, et al. Medication management in patients with dysphagia: a service evaluation. Nurs Stand. 2013;27(41):41–48
Kelly J, et al. Medicine administration errors in patients with dysphagia in secondary care: a multi‐centre observational study. J Adv Nurs. 2011;67(12):2615–2627
Dyer AM, Smith A. Riluzole 5 mg/mL oral suspension: for optimized drug delivery in amyotrophic lateral sclerosis. Drug Des Devel Ther. 2017;11:59–64
Royal Pharmaceutical Society. Pharmaceutical issues when crushing, opening or splitting oral dosage forms. Available at: www.rpharms.com/Portals/0/RPS%20document%20library/Open%20access/Support/toolkit/pharmaceuticalissuesdosageforms-%282%29.pdf. Last accessed: November 2022
Teglutik. Summary of Product Characteristics
Data on File. EN011: Price opportunity assessment and market access strategy for Riluzole Oral Film (ROF) – patient preference study in DE, ES, IT. Final Report 17 Aug 2022
Onesti E, et al. Dysphagia in amyotrophic lateral sclerosis: impact on patient behavior, diet adaptation, and riluzole management. Front Neurol. 2017;8:94
Aquestive. PharmFilm® Drug Delivery Technology: Addressing unmet patient needs to improve disease management. Available at: http://pharmfilmeducation.com. Last accessed: November 2022
Di Stefano, et al. Randomised, 2-sequence, 4-period replicate cross-over bioequivalence study of a new riluzole orodispersible film vs. a reference tablet in healthy volunteers. J Bioeq Stud. 2022;8(1). Currently in press
ClinicalTrials.gov: NCT03679975. Available at: https://clinicaltrials.gov/ct2/show/NCT03679975. Last accessed: November 2022
Data on File. Riluzole Oral Film, NDA 212640. Clinical Study Report
GB_ROF_029
April 2023